SCHEMBL2444946

SCHEMBL2444946

CCCCCCCC[C@H]1CCC[C@@]1(CCCCCCN)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 3/20 0.37
ARG2 P78540 2/20 0.37
CPB2 Q96IY4 5/20 0.36
AKT1 P31749 7/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2137919 0.93 ARG1 (0.38) ARG1ARG2AKT1
SCHEMBL8411260 0.89 ALOX5 (0.36) ARG1ARG2AKT1
SCHEMBL8667941 0.89 ALOX5 (0.36) ARG1ARG2AKT1
SCHEMBL14697385 0.89 ALOX5 (0.36) ARG1ARG2AKT1
SCHEMBL16652985 0.89 ALOX5 (0.36) ARG1ARG2AKT1
SCHEMBL16653037 0.89 ALOX5 (0.36) ARG1ARG2AKT1
SCHEMBL9514241 0.88 ARG1 (0.34) ARG1ARG2
SCHEMBL11627387 0.86 ALOX15 (0.39) ARG1ARG2
SCHEMBL1724499 0.83 TDP1 (0.37) ARG1ARG2AKT1
SCHEMBL14697190 0.82 NAAA (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-53046969-A None JP disclosed
JP-53046970-A None JP disclosed
JP-52091856-A None JP disclosed
JP-51128961-A None JP disclosed
JP-51128962-A None JP disclosed
EP-1481976-B1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2012-11-07 EP disclosed
US-8026273-B2 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2011-09-27 US disclosed
US-20100113388-A1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-7683094-B2 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2010-03-23 US disclosed
US-20090042885-A1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2009-02-12 US disclosed
US-7402605-B2 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-07-22 US disclosed
US-20050124577-A1 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-09 US disclosed
EP-1481976-A1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-12-01 EP disclosed
US-4113873-A 8-AZAPROSTANOIC ACID DERIVATIVES TANABE SEIYAKU CO. LTD. (JP) 1978-09-12 US disclosed
US-4113873-A 8-AZAPROSTANOIC ACID DERIVATIVES TANABE SEIYAKU CO. LTD. (JP) 1978-09-12 US disclosed
JP-S5346970-A 8-AZAPROSTANOIC ACIDS AND THEIR PREPARATION TANABE SEIYAKU CO LTD 1978-04-27 JP disclosed
JP-S5346969-A 8-AZAPROSTANOIC ACIDS AND THEIR PREPARATION TANABE SEIYAKU CO LTD 1978-04-27 JP disclosed
JP-S5291856-A 2-PYRROLIDONE DERIVATIVES TANABE SEIYAKU CO LTD 1977-08-02 JP disclosed
JP-S51128962-A PROCESS FOR PREPARING 8-AZAPROSTANOIC ACID DERIVATIVES TANABE SEIYAKU CO LTD 1976-11-10 JP disclosed
JP-S51128961-A PROCESS FOR PREPARING 8-AZAPROSTANOIC ACID DERIVATIVES TANABE SEIYAKU CO LTD 1976-11-10 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124577-A1 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient PTGER2, PTGIS, HPGDS ARG1 1924/4885ARG2 850/4885CPB2 442/4885
US-20090042885-A1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT PTGER2, PTGIS, HPGDS ARG1 2268/4885ARG2 1291/4885CPB2 410/4885
US-20100113388-A1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT PTGER2, PTGIS, HPGDS ARG1 2268/4885ARG2 1291/4885CPB2 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.